德国瘤学的门诊常规护理:现实世界生存数据
Norbert Marschner1,2, Wolfgang Knauf3,4
1Klinisches Forschungsinstitut iOMEDICO, Freiburg, Germany.
Oncology research and treatment
|March 17, 2024
概括
德国的现实癌症存活率与临床试验数据相匹配,即使是患病更严重的患者. 这项研究弥合了晚期癌症的疗效差距,在常规护理环境中显示了类似的结果.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 现实世界的证据.
背景情况:
- 随机对照试验 (RCT) 涉及高度精选的患者,限制了对现实世界人口的概括性.
- 在现实世界中,患者往往年龄较大,患上更多的并发病,健康状况较差,造成了疗效差距.
- 与临床试验相比,这种差距通常导致常规医疗保健中的生存结果较差.
研究的目的:
- 为了比较在德国常规医疗机构治疗的晚期癌症患者的整体存活率 (OS),与关键随机对照试验 (RCT) 相比.
- 调查血液瘤学实践中系统癌症治疗中的疗效差距的程度.
主要方法:
- 分析了来自德国6个前性临床瘤注册表的数据 (2006-2020年),其中包括11,679名患有晚期结直肠癌,乳腺癌,肺癌,胰腺癌,细胞癌和淋巴瘤的患者.
- 对常规护理患者的系统治疗结果和整体存活率进行了分析.
- 通过文献搜索,确定了可比的关键RCT用于生存数据比较.
主要成果:
- 在德国常规护理中,晚期结肠直肠,乳腺,肺癌,胰腺癌,扩散性大B细胞淋巴瘤和多发性骨髓瘤的平均整体存活期与RCT数据相似.
- 与试验数据相比,患有晚期细胞癌,慢性淋巴细胞白血病和惰性非霍奇金淋巴瘤的患者在常规护理中生存率略低.
- 在常规护理中,对于大多数研究的晚期癌症,没有观察到显著的生存劣势.
结论:
- 德国门诊常规护理中的癌症患者存活率与随机对照研究结果一致,尽管患者特征不那么有利.
- 对于几种在常规血液瘤实践中治疗的晚期癌症,疗效差距似乎很小.
- 现实世界的数据支持在常规护理环境中全身疗法的有效性,与试验有效性相比.
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:24Kaplan-Meier Approach
136
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
136
01:20Comparing the Survival Analysis of Two or More Groups
183
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
183